PURPOSE: We identify sites and patterns of cancer recurrence in patients with post-prostatectomy biochemical relapse using 11C-choline positron emission tomography/computerized tomography and endorectal coil multiparametric magnetic resonance imaging. MATERIALS AND METHODS: Between January 2008 and June 2015, 2,466 men underwent choline positron emission tomography for suspected prostate cancer relapse at our institution. Of these men 202 did not receive hormone or radiation therapy, underwent imaging with choline positron emission tomography and multiparametric magnetic resonance imaging, and were found to have disease recurrence. Overall patterns of recurrence were described, and factors associated with local only recurrence were evaluated using univariable and multivariable logistic regression. RESULTS: Median prostate specific antigen at positive scan was 2.3 ng/ml (IQR 1.4-5.5) with a median time from prostate specific antigen relapse to lesion visualization of 15 months (IQR 4.8-34.2). Of these 202 men 68 (33%) exhibited local only, 45 (22%) local plus metastatic and 89 (45%) metastatic only relapse. Pelvic node only relapse was observed in 39 (19%) men. Median prostate specific antigen at positive imaging for patients with local only, metastatic only and local plus metastatic relapse was 2.3, 2.7 and 2.2 ng/ml (p=0.46), with a median interval from biochemical recurrence to positive scan of 33.5, 7.0 and 15.0 months, respectively (p <0.001). On multivariable analysis time from biochemical recurrence to positive imaging was independently associated with local only recurrence (OR 1.10 for every 6-month increase, p=0.012). CONCLUSIONS: Combined choline positron emission tomography and multiparametric magnetic resonance imaging evaluation of biochemical recurrence after prostatectomy reveals an anatomically diverse pattern of recurrence. These findings have implications for optimizing the salvage treatment of patients with prostate cancer with relapse following surgery. Copyright Â
PURPOSE: We identify sites and patterns of cancer recurrence in patients with post-prostatectomy biochemical relapse using 11C-choline positron emission tomography/computerized tomography and endorectal coil multiparametric magnetic resonance imaging. MATERIALS AND METHODS: Between January 2008 and June 2015, 2,466 men underwent choline positron emission tomography for suspected prostate cancer relapse at our institution. Of these men 202 did not receive hormone or radiation therapy, underwent imaging with choline positron emission tomography and multiparametric magnetic resonance imaging, and were found to have disease recurrence. Overall patterns of recurrence were described, and factors associated with local only recurrence were evaluated using univariable and multivariable logistic regression. RESULTS: Median prostate specific antigen at positive scan was 2.3 ng/ml (IQR 1.4-5.5) with a median time from prostate specific antigen relapse to lesion visualization of 15 months (IQR 4.8-34.2). Of these 202 men 68 (33%) exhibited local only, 45 (22%) local plus metastatic and 89 (45%) metastatic only relapse. Pelvic node only relapse was observed in 39 (19%) men. Median prostate specific antigen at positive imaging for patients with local only, metastatic only and local plus metastatic relapse was 2.3, 2.7 and 2.2 ng/ml (p=0.46), with a median interval from biochemical recurrence to positive scan of 33.5, 7.0 and 15.0 months, respectively (p <0.001). On multivariable analysis time from biochemical recurrence to positive imaging was independently associated with local only recurrence (OR 1.10 for every 6-month increase, p=0.012). CONCLUSIONS: Combined choline positron emission tomography and multiparametric magnetic resonance imaging evaluation of biochemical recurrence after prostatectomy reveals an anatomically diverse pattern of recurrence. These findings have implications for optimizing the salvage treatment of patients with prostate cancer with relapse following surgery. Copyright Â
Authors: Alan Dal Pra; Cedric Panje; Thomas Zilli; Winfried Arnold; Kathrin Brouwer; Helena Garcia; Markus Glatzer; Silvia Gomez; Fernanda Herrera; Khanfir Kaouthar; Alexandros Papachristofilou; Gianfranco Pesce; Christiane Reuter; Hansjörg Vees; Daniel Rudolf Zwahlen; Daniel Engeler; Paul Martin Putora Journal: Strahlenther Onkol Date: 2017-06-27 Impact factor: 3.621
Authors: Jeremie Calais; Johannes Czernin; Minsong Cao; Amar U Kishan; John V Hegde; Narek Shaverdian; Kiri Sandler; Fang-I Chu; Chris R King; Michael L Steinberg; Isabel Rauscher; Nina-Sophie Schmidt-Hegemann; Thorsten Poeppel; Philipp Hetkamp; Francesco Ceci; Ken Herrmann; Wolfgang P Fendler; Matthias Eiber; Nicholas G Nickols Journal: J Nucl Med Date: 2017-11-09 Impact factor: 10.057
Authors: Verane Achard; Giorgio Lamanna; Antoine Denis; Thomas De Perrot; Ismini Charis Mainta; Osman Ratib; Christophe Iselin; Raymond Miralbell; Valentina Garibotto; Thomas Zilli Journal: Med Oncol Date: 2019-06-12 Impact factor: 3.064
Authors: Lars J Petersen; Julie B Nielsen; Katja Dettmann; Rune V Fisker; Uwe Haberkorn; Louise Stenholt; Helle D Zacho Journal: Mol Clin Oncol Date: 2017-05-31
Authors: Andrei Fodor; Andrea Lancia; Francesco Ceci; Maria Picchio; Morten Hoyer; Barbara Alicja Jereczek-Fossa; Piet Ost; Paolo Castellucci; Elena Incerti; Nadia Di Muzio; Gianluca Ingrosso Journal: World J Urol Date: 2018-05-11 Impact factor: 4.226
Authors: Jaden D Evans; Lindsay K Morris; Henan Zhang; Siyu Cao; Xin Liu; Kristin C Mara; Bradley J Stish; Brian J Davis; Aaron S Mansfield; Roxana S Dronca; Matthew J Iott; Eugene D Kwon; Robert L Foote; Kenneth R Olivier; Haidong Dong; Sean S Park Journal: Int J Radiat Oncol Biol Phys Date: 2018-09-08 Impact factor: 7.038
Authors: Felipe Couñago; Gemma Sancho; Violeta Catalá; Diana Hernández; Manuel Recio; Sara Montemuiño; Jhonathan Alejandro Hernández; Antonio Maldonado; Elia Del Cerro Journal: World J Clin Oncol Date: 2017-08-10
Authors: Ciro Franzese; Paolo Andrea Zucali; Lucia Di Brina; Giuseppe D'Agostino; Pierina Navarria; Davide Franceschini; Armando Santoro; Marta Scorsetti Journal: Cancer Med Date: 2018-08-02 Impact factor: 4.452